A pill for dermatomyositis arrives with no augmentation-therapy caveat attached
The FDA approved brepocitinib for dermatomyositis, a disease affecting up to 70,000 Americans with no dedicated drug until now.
By The Weekend · · 4 min read
On Thursday the FDA approved brepocitinib, sold as Lisraya, for dermatomyositis — a rare autoimmune disease that has never had a medicine designed specifically for it. The drug is a once-daily pill from Roivant and its subsidiary Priovant. Everyone currently being treated for this disease is being treated with something built for other diseases.
Zero is the number the approval erases
Dermatomyositis affects between 40,000 and 70,000 people in the United States, according to Roivant's own estimate. Until this week, the standard of care was high-dose steroids and other immune-suppressing drugs — medicines developed and approved for lupus, rheumatoid arthritis, organ transplant rejection, and a dozen other conditions, then borrowed for a disease that causes muscle weakness and a distinctive, painful skin rash. Brepocitinib is the first drug the FDA has approved with dermatomyositis as its primary indication. That "zero to one" is the actual event. The pill itself, a JAK inhibitor that blocks a signaling pathway immune cells use to drive inflammation, is not a new mechanism — JAK inhibitors have been on the market for arthritis and other autoimmune conditions since 2012. What's new is that a company ran the trials, gathered the data, and got the FDA to sign off on this specific disease, rather than leaving doctors to extrapolate from steroid protocols and educated guesswork.
Borrowed treatment isn't the same as no treatment
It's worth being precise about what the absence of a dedicated drug did and didn't mean for patients. Steroids and immunosuppressants do work, to a degree, for many people with dermatomyositis — this wasn't a disease left completely untreated. But high-dose, long-term steroid use carries its own well-documented costs: bone density loss, weight gain, elevated blood sugar, cataracts, and increased infection risk, all worse the longer a patient stays on them. A drug developed and tested specifically for dermatomyositis, with a dosing and safety profile built around that patient population rather than borrowed from lupus trials, is a meaningfully different proposition even before anyone asks how well it works compared to steroids head-to-head. The size of the win depends entirely on that comparison, which will take longer to establish than the approval itself.
The strongest objection: JAK inhibitors carry a boxed warning for a reason
The FDA has required a boxed warning — its most serious label warning — on JAK inhibitors as a class since 2021, after a large safety trial of tofacitinib in rheumatoid arthritis patients found increased risks of heart attack, stroke, cancer, blood clots and death compared with older drugs called TNF inhibitors. That trial, known as ORAL Surveillance, enrolled patients aged 50 and older with at least one cardiovascular risk factor — an important qualifier, since it means the warning applies most directly to an older, higher-risk population rather than to every person who might take a JAK inhibitor. Regulators extended the warning across the drug class as a precaution. Anyone prescribed brepocitinib for dermatomyositis will be taking a drug from a family that carries that label, and doctors will need to weigh cardiovascular and clotting risk against the disease it's treating — a genuinely serious tradeoff, not a formality.
What the pill actually changes for a patient this year
For someone newly diagnosed, the practical difference is a first-line option that doesn't require the same steroid taper-and-monitor routine, and a manufacturer with a specific incentive to study side effects, dosing and long-term outcomes in this disease rather than treating it as an afterthought to a bigger indication. For someone already stable on an existing regimen, the calculation is murkier: switching a working treatment for a newly approved one means trading a known set of risks for a different, less time-tested one. Pricing hasn't been disclosed yet, and that number will matter as much as the trial data — rare-disease drugs approved through this kind of pathway routinely carry list prices in the tens of thousands of dollars annually, and insurers' willingness to cover a new entrant when older, cheaper immunosuppressants already exist is its own separate fight, one that will play out in formulary decisions long after the approval headline fades.
Rare-disease approvals run on economics, not just biology
Dermatomyositis sits in a category regulators and drugmakers call rare disease — under 200,000 US patients — which comes with its own incentive structure: orphan drug designation, extended market exclusivity, and smaller, faster trials than a common-disease drug would require. That's not a criticism of the approval; it's the mechanism that made it commercially viable to run trials for a disease of 40,000 to 70,000 people in the first place, when the same R&D budget could chase a market ten times the size. It's also why the first dedicated dermatomyositis drug is arriving now rather than twenty years ago — the regulatory and financial architecture for rare-disease drug development has matured, and JAK inhibitors, already validated in bigger markets, were a lower-risk mechanism to repurpose than building something from scratch.
What happens next is the ordinary unglamorous work of any new drug: post-marketing surveillance to catch the safety signals a few hundred trial participants couldn't reveal, real-world data on how it performs against steroids in patients who aren't idealized trial candidates, and a price tag that will determine how many of the 40,000 to 70,000 eligible patients ever get access to it. The approval is the headline. Whether it changes outcomes for most people with the disease is a question that won't have an answer for a few years yet.